Voyager Therapeutics (VYGR) Hisse Özeti
Bir biyoteknoloji şirketi olan Voyager Therapeutics, Inc. nörolojik hastalıkların tedavisi için insan genetiğine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
VYGR Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% değerinin altında içsel indirim
5419.8%Revenue growth p.a.
6.2k
18
0
126
Voyager Therapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.76 |
| 52 Haftanın En Yüksek Seviyesi | US$5.55 |
| 52 Haftanın En Düşük Seviyesi | US$2.65 |
| Beta | 1.38 |
| 1 Aylık Değişim | -5.76% |
| 3 Aylık Değişim | -3.59% |
| 1 Yıllık Değişim | 3.30% |
| 3 Yıllık Değişim | -53.35% |
| 5 Yıllık Değişim | -12.76% |
| Halka arzdan bu yana değişim | -78.82% |
Son Haberler & Güncellemeler
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Apr 13VYGR: Future P/E Stability Will Support Upside From Cash And Milestone Optionality
Analysts maintained their Voyager Therapeutics price target at $25.00, citing only minor adjustments in assumptions such as discount rate, revenue growth, profit margin and future P/E that did not materially affect their overall valuation view. Valuation Changes Fair Value: Held steady at $25.00 per share, with no change in the analysts' central estimate.VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their Voyager Therapeutics price target steady at $25.00, with updated assumptions reflecting a slightly lower discount rate, more measured revenue growth, a much slimmer profit margin, and a very large projected future P/E multiple. Together, these factors signal a more cautious outlook on profitability while holding the same headline valuation.Recent updates
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Apr 13VYGR: Future P/E Stability Will Support Upside From Cash And Milestone Optionality
Analysts maintained their Voyager Therapeutics price target at $25.00, citing only minor adjustments in assumptions such as discount rate, revenue growth, profit margin and future P/E that did not materially affect their overall valuation view. Valuation Changes Fair Value: Held steady at $25.00 per share, with no change in the analysts' central estimate.VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their Voyager Therapeutics price target steady at $25.00, with updated assumptions reflecting a slightly lower discount rate, more measured revenue growth, a much slimmer profit margin, and a very large projected future P/E multiple. Together, these factors signal a more cautious outlook on profitability while holding the same headline valuation.VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their $25.00 price target for Voyager Therapeutics unchanged, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that offset each other overall. Valuation Changes Fair Value: $25.00 unchanged, with the updated inputs offsetting each other in the model.VYGR: Refined Assumptions Will Reinforce Upside From Cash And Milestone Optionality
Analysts kept their $25.00 price target for Voyager Therapeutics unchanged, noting only very small tweaks in the discount rate, revenue growth assumptions, profit margin, and future P/E that do not materially alter their view. Valuation Changes Fair Value: Kept steady at $25.00, with no change in the estimated intrinsic value per share.VYGR: Neuro Data Readouts Will Reframe Upside From Cash And Milestone Optionality
Narrative Update Analysts trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing the latest cash position of US$229m, potential partner milestones of up to US$2.4b, and progress in NeuroShuttle non viral delivery programs as key inputs to their updated outlook. Analyst Commentary Bullish analysts see the latest price target move to US$25 as a reset that still implies upside from current levels, supported by what they view as a solid capital position and a growing partnered pipeline.VYGR: Cash Strength And Milestone Upside Will Drive Neuro Data Repricing
Narrative Update on Voyager Therapeutics Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing strong Q3 cash of US$229m, eligibility for up to US$2.4b in partner milestones, and upcoming NeuroShuttle data as key factors shaping their outlook. Analyst Commentary Bullish analysts are adjusting their views while still highlighting what they see as solid execution and a meaningful cash position at Voyager Therapeutics.VYGR: Cash And Milestone Optionality Will Support Upcoming Neuro Data Repricing
Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing updated assumptions around future P/E multiples, while also highlighting the company’s Q3 cash position of US$229m, potential partner milestones of up to US$2.4b, and upcoming NeuroShuttle data as key drivers for the outlook. Analyst Commentary Bullish analysts continue to see a constructive setup for Voyager Therapeutics, even with the reduced price target, pointing to cash resources, milestone potential, and the NeuroShuttle platform as the core pieces of the story.VYGR: Cash Runway And Milestone Potential Will Drive Upside Ahead
Analysts have reduced their price target on Voyager Therapeutics by $5 to $25 per share, reflecting a modestly higher discount rate. They continue to highlight robust cash runway, significant milestone potential, and advancing NeuroShuttle data as key long term value drivers.Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet
Nov 15
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 14Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%
Sep 25It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year
May 27Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Feb 25Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Jan 30
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Nov 18Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Oct 17Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Hissedar Getirileri
| VYGR | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -0.8% | -2.5% | 0.8% |
| 1Y | 3.3% | 26.8% | 27.7% |
Getiri vs. Endüstri: VYGR geçen yıl % 26.8 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: VYGR geçen yıl % 27.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| VYGR volatility | |
|---|---|
| VYGR Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
İstikrarlı Hisse Senedi Fiyatı: VYGR son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: VYGR 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2013 | 141 | Al Sandrock | www.voyagertherapeutics.com |
Bir biyoteknoloji şirketi olan Voyager Therapeutics, Inc. nörolojik hastalıkların tedavisi için insan genetiğine odaklanmaktadır. Ürün hattı, tau susturucu gen terapisi olan VY1706 ve alzheimer hastalığının tedavisi için bir anti-tau antikor programı olan VY7523'ü içermektedir. Şirket ayrıca Huntington hastalığının tedavisi için araştırma programı sunmaktadır.
Voyager Therapeutics, Inc. Temel Bilgiler Özeti
| VYGR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$222.31m |
| Kazançlar(TTM) | -US$119.72m |
| Gelir(TTM) | US$40.37m |
5.6x
P/S Oranı-1.9x
F/K OranıVYGR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| VYGR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$40.37m |
| Gelir Maliyeti | US$132.27m |
| Brüt Kâr | -US$91.90m |
| Diğer Giderler | US$27.82m |
| Kazançlar | -US$119.72m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.01 |
| Brüt Marj | -227.62% |
| Net Kâr Marjı | -296.53% |
| Borç/Özkaynak Oranı | 0% |
VYGR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/01 08:48 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Voyager Therapeutics, Inc. 26 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Brian Skorney | Baird |
| Jack Allen | Baird |
| Aydin Huseynov | Benchmark Company |